Bioglutide (NA-931): Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โขCommunity protocols detailed below
- โขEvidence level: Anecdotal Reports
- โขSee community reports below
- โขStacking patterns detailed below
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Availability | Bioglutide (NA-931) is in Phase 2 development by Biomed Industries. Available only through clinical trials. | No community access exists. Bioglutide's proprietary structure and early development stage mean it is not available from any research chemical vendor. Community discussion is entirely analytical. | high As a proprietary small molecule derived from a cyclic IGF-1 fragment, bioglutide cannot be replicated through standard peptide synthesis or compounding. |
| Quadruple Agonism | Bioglutide simultaneously targets IGF-1, GLP-1, GIP, and glucagon receptors, making it the first quadruple agonist in clinical development for obesity. | Community interest is driven by the novel quadruple mechanism and the impressive Phase 2 results (13.8% weight loss at 13 weeks with minimal GI side effects). The rapid weight loss and favorable tolerability profile are frequently discussed. | moderate The addition of IGF-1 receptor agonism to the GLP-1/GIP/glucagon combination is unique and may contribute to the reported muscle mass preservation during weight loss. |
Compare these community approaches with published research findings.
Sources
- Reddit r/Peptides|Bioglutide NA-931 and quadruple agonist discussions(accessed 2026-02-16)
- Reddit r/Semaglutide|Next-generation oral obesity treatments including bioglutide(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Bioglutide (NA-931). The information below is gathered from Reddit communities and online forums. This is not clinical evidence and should not be used as medical guidance.
Bioglutide has generated community interest due to its novel quadruple agonist mechanism and impressive early clinical data, but no community use exists.
Early Development Stage#
Bioglutide (NA-931) is in Phase 2 clinical development by Biomed Industries. It is not available outside clinical trials. Community discussion is entirely based on analysis of early clinical data.
Community Interest Drivers#
Bioglutide's Phase 2 data has generated excitement for several reasons:
- Rapid weight loss: 13.8% in just 13 weeks (faster trajectory than most competitors)
- Minimal GI side effects: 83% of adverse events rated as insignificant, addressing the major tolerability concern with GLP-1 agonists
- Oral administration: Once-daily capsule without the food/water restrictions of oral semaglutide
- Muscle mass preservation: IGF-1 receptor agonism may help prevent lean mass loss during weight loss
- Quadruple receptor targeting: Novel mechanism not replicated by any other compound in development
Important Caveats#
- Phase 2 data from small sample size; requires Phase 3 confirmation
- Not available outside clinical trials
- Proprietary compound that cannot be synthesized or compounded
- No community use data exists
- Smaller biotech company (Biomed Industries) with uncertain development timeline
- Early-stage results often do not fully replicate in larger trials
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Bioglutide (NA-931)
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.